Trial in Adult Participants With Spinocerebellar Ataxia (SCA)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

141

Participants

Timeline

Start Date

December 15, 2016

Primary Completion Date

August 18, 2017

Study Completion Date

September 20, 2024

Conditions
Spinocerebellar AtaxiasSpinocerebellar Ataxia Genotype Type 1Spinocerebellar Ataxia Genotype Type 2Spinocerebellar Ataxia Genotype Type 3Spinocerebellar Ataxia Genotype Type 6Spinocerebellar Ataxia Genotype Type 7Spinocerebellar Ataxia Genotype Type 8Spinocerebellar Ataxia Genotype Type 10
Interventions
DRUG

Troriluzole

Randomization Phase: Neat (i.e., drug substance without excipients); loose filled capsule.

DRUG

Placebo

Drug: Placebo Randomization Phase: Matching placebo loose filled capsule.

DRUG

Troriluzole

OLE phase: Neat capsule or formulated capsule (i.e., drug substance with excipients).

Trial Locations (18)

10032

Columbia University, New York

14642

University of Rochester Medical Center, Rochester

21287

Johns Hopkins University, Baltimore

30329

Emory University, Atlanta

32611

University of Florida, Gainesville

33612

University of South Florida, Tampa

48105

University of Michigan, Ann Arbor

60611

Northwestern University, Chicago

60637

University of Chicago, Chicago

75390

University of Texas Southwestern, Dallas

77030

Houston Methodist Research Center, Houston

80045

University of Colorado Denver, Denver

85013

St. Joseph's Hospital and Medical Center, Phoenix

90095

University of California, Los Angeles, Los Angeles

90806

CNS Trial, Long Beach

94158

University of California, San Francisco, San Francisco

02114

Harvard University (Massachusetts General Hospital), Boston

02215

Harvard University (Beth Israel Deaconess Medical Center), Boston

Sponsors
All Listed Sponsors
lead

Biohaven Pharmaceuticals, Inc.

INDUSTRY